D. E. Shaw & Co. Inc. grew its stake in Jounce Therapeutics Inc (NASDAQ:JNCE) by 35.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,776 shares of the company’s stock after buying an additional 24,572 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Jounce Therapeutics were worth $316,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in JNCE. JPMorgan Chase & Co. boosted its holdings in Jounce Therapeutics by 153.0% during the third quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock worth $2,861,000 after purchasing an additional 266,126 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Jounce Therapeutics by 130.6% during the fourth quarter. Acadian Asset Management LLC now owns 139,957 shares of the company’s stock worth $471,000 after purchasing an additional 79,266 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Jounce Therapeutics during the third quarter worth $677,000. Virtu Financial LLC acquired a new position in Jounce Therapeutics during the fourth quarter worth $111,000. Finally, BlackRock Inc. boosted its holdings in Jounce Therapeutics by 4.0% during the third quarter. BlackRock Inc. now owns 1,450,680 shares of the company’s stock worth $9,429,000 after purchasing an additional 55,775 shares during the last quarter. Institutional investors own 72.65% of the company’s stock.
Shares of JNCE opened at $5.87 on Tuesday. Jounce Therapeutics Inc has a 12 month low of $2.66 and a 12 month high of $22.44. The firm has a market cap of $204.74 million, a P/E ratio of -6.98 and a beta of 3.90.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.29. Jounce Therapeutics had a negative net margin of 41.99% and a negative return on equity of 25.69%. The firm had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.86 million. Analysts forecast that Jounce Therapeutics Inc will post -1.2 EPS for the current fiscal year.
Several research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Tuesday, January 22nd. JPMorgan Chase & Co. restated a “sell” rating on shares of Jounce Therapeutics in a report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $11.67.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Read More: NASDAQ
Want to see what other hedge funds are holding JNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jounce Therapeutics Inc (NASDAQ:JNCE).
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.